How do Real World Data (RWD) and Real World Evidence (RWE) professionals see their critical role developing?
- Which teams are using RWD/RWE, where is it providing most value and how might this change over the next 2 years?
- What are the main challenges faced by RWD/RWE professionals?
- How is the collection of RWD/RWE planned and what factors drive these decisions?
- When in a product’s lifecycle should RWD/RWE collection start and how might this change?
RWD and RWE play an increasingly important role in proving the value and utility of drugs. The insights provided go beyond clinical research results and regulatory approval to deliver persuasive real world evidence to key stakeholders such as payers. Yet RWD/RWE professionals face a number of challenges and the discipline is having to adapt to ever increasing workloads and developing market demands.
Via the Institute of Cancer Research:
We set out to assess the current landscape for drug discovery and development by analyzing every cancer drug first licensed through the European Medicines Agency (EMA) from 2000 to 2016.
We identified all cancer drugs that were first licensed by the EMA and listed on its database from Jan. 1, 2000, until Dec. 31, 2016.
We chose to look at licensing through the EMA because of its relevance to drug access in the U.K. We recorded both the first drug authorization and all subsequent licensed indications. To look for changing trends over time, we split the data into two consecutive time periods, from 2000 to 2008, and from 2009 to 2016, and then carried out comparative analyses.
We examined how quickly drugs are moving along the development pipeline from their initial discovery through clinical trials and on to EMA authorization and then appraisal by NICE. We also assessed how innovative each drug was, in order to evaluate what difference this made to its chances of being successfully approved for NHS patients.
Nick Jones of BD Consulting conducted data collection and analysis with the policy team at the Institute of Cancer Research (ICR), overseen by the ICR’s scientific leadership.
A growing number of biologic medicines have been developed and approved over the past decade, improving the lives of patients worldwide.
Although these have been effective at treating numerous diseases, patient access has been limited, partly due to their relatively high cost. As biologics lose their patent-protection, many biosimilars are becoming available across Europe, and manufacturers are seeking to bring additional biosimilar products to market.
These are expected to bring with them the opportunity to generate competition for biologic therapies and thereby lower costs and increase patient access. However, some biosimilar policies and purchasing mechanisms limit participation of competitor products in specific markets, apply increasing price pressure or push physicians to switch patient product use.
These current dynamics have raised questions about the sustainability of the biosimilars market in the long-term.
Evidence-based care leads to better clinical outcomes, but how does it affect your cost?
A multi-year study performed in association with professionals from Abramson Cancer Center of the University of Pennsylvania and Johns Hopkins Carey Business School revealed that the cost of unwarranted components of oncology treatments averaged $25,579 per patient.
At current annual cancer incidence rates in the US, this translates to over $10 billion per year in unnecessary costs that could be significantly reduced by eliminating unwarranted, non-evidence-based cancer treatment.
Health economics and outcomes research (HEOR) and market access agencies provide specialist consultancy support to pharmaceutical and medical device companies throughout the lifecycle (early phase, pre-launch, launch and post-launch) of a technology (pharmaceutical drug or medical device).
The types of agencies that offer HEOR and market access consultancy support vary widely. They include medical communications (MedComms) agencies that offer these specialist services, and other companies that are dedicated exclusively to either HEOR or market access work (some provide integrated support across both disciplines).
In any of these agency types, as a medical writer working alongside team members with a wide range of skills, you will be involved in the generation and communication of evidence to demonstrate the added value of a technology, and its potential in clinical practice, to healthcare decision makers.
ConnectiveRx recently conducted a survey of over 250 prescribers to understand the potential prescribing impact of delivering in-EHR patient drug prices.
This white paper explores the key findings of that research and the potential impact on brand market share.
How does exposure to brand savings offers impact prescribing?
The challenges of managing prescription drug benefits continue to make today’s news. Headlines feature the hardships of soaring drug prices and the growing number of innovative drug approvals. As health care spending continues to outpace the economy, the need for changes in drug management intensifies.
This led Anthem Inc. to launch IngenioRx, a new pharmacy benefit manager (PBM) that will offer a full suite of services in 2020. The goal of IngenioRx is to improve health outcomes, reduce total health care costs, and provide consumers a simplified experience in a highly fragmented and confusing health care system.
IngenioRx will serve customers of Anthem’s affiliated health plans, as well as non-Anthem customers, with a seamless, consumer-centric approach to managing health and driving better outcomes. To accomplish this, clinical experts use integrated pharmacy + medical data and perspectives to guide decision making and effective use of traditional and non-traditional management tools. This allows us to achieve meaningful clinical outcomes at an affordable price. The ability to see the whole picture enables an examination of the total drug trend and provides insights and recommendations that go well beyond a traditional PBM.
With the launch of IngenioRx last year, we are proud to provide you with our inaugural annual drug trend report, detailing the 2017 consolidated pharmacy + medical drug trends for Anthem’s affiliated health plans, which will feature pharmacy benefits powered by IngenioRx beginning in 2020. We look forward to expanding and enhancing these strategies and solutions as we grow our pharmacy business within Anthem’s existing footprint and beyond.
The healthcare industry’s claims-payment system is frustrating to providers, payers, and patients alike. Inefficiency and a systemwide tendency for error wastes resources, worsens miscommunication and mistrust among all stakeholders, and inhibits the ability to transition to value-based approaches that achieve better outcomes.
Learn how the drive for accurate adjudication across the claims-payment continuum can optimize processes, reduce costs, align systems and stakeholders, and bring value-based payment models to scale.
With many payers focusing resources on a small percentage of chronically ill patients, a large portion of the member population remains unmonitored and engaged.
Patient engagement programs that are scalable, multi-layered, and tech-enabled to reach members in the most convenient and effective ways are essential to creating a positive member experience, driving loyalty, cost reduction, and better adherence.
As the largest payer of healthcare services in the United States, the Centers for Medicare and Medicaid Services (CMS) oftensets trend for healthcare delivery and reimbursement.
Over the past few years, there has been talk about Medicare reform and how to better pay for value. But we don’t always take the time to step back and appreciate what works well in Medicare and what has been emulated by other stakeholders.
For example, when Congress enacted the Average Sales Price (ASP) reimbursement methodology for Part B drugs in 2003, many commercial payers followed suit. This was with good reason: ASP is a transparent and stable metric that aligns reimbursement with market prices. Most recently, Medicare has again led the charge in adopting value-based reforms,creating ripple effects throughout the healthcare marketplace.
Four areas where we think Medicare has got it right are reimbursing physician-administered drugs, enabling beneficiary choice through Medicare Advantage, looking at total cost of care and tying payment to quality.